Fatty Liver Disease and GLP-1 Inhibitors: A Cardiologist's Guide to Metabolic and Heart Protection

For many years, fatty liver was referred to as Non-Alcoholic Fatty Liver Disease (NAFLD). Recently, the international medical community updated the terminology to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) to reflect its true cause: metabolic dysregulation. MASLD is diagnosed when there is excess fat accumulation in the liver alongside at least one metabolic risk factor, such as high blood pressure, elevated glucose, high cholesterol, or obesity. It is a silent epidemic in Singapore, affecting an estimated 30% to 40% of adults. Because it shares the exact same underlying drivers as cardiovascular disease — insulin resistance and systemic inflammation — a fatty liver serves as a clear warning sign that your blood vessels and heart may also be under stress.

How does fat in the liver affect the heart? The liver is the body's metabolic engine. When it becomes overloaded with fat, it triggers a cascade of negative effects throughout the cardiovascular system. First, fatty liver promotes chronic, low-grade systemic inflammation. The liver releases inflammatory cytokines (such as IL-6 and TNF-alpha) into the bloodstream, which directly damage the endothelial lining of blood vessels, promoting the formation of arterial plaques. Second, MASLD worsens insulin resistance, leading to higher levels of circulating triglycerides and small, dense LDL particles — the highly atherogenic type of cholesterol that causes heart attacks. Consequently, clinical studies show that patients with MASLD have a 1.6-fold to 2-fold increased risk of developing coronary artery disease, independent of other risk factors.

Patients frequently ask about ‘GLP-1 inhibitors’ for weight loss and fatty liver. In clinical practice, these medications are actually called GLP-1 receptor agonists. They work by mimicking Glucagon-Like Peptide-1 (GLP-1), a hormone naturally released by the gut after eating. GLP-1 stimulates insulin release in response to meals, slows stomach emptying to increase fullness, and acts on the brain to reduce appetite. In contrast, the term ‘inhibitor’ is typically used for DPP-4 inhibitors (like sitagliptin), which prevent the breakdown of the body's natural GLP-1 but are much less potent. The most commonly prescribed GLP-1 receptor agonists in Singapore include semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda). Additionally, dual GIP/GLP-1 agonists like tirzepatide (Mounjaro, Zepbound) provide even greater metabolic benefits.

While initially developed for type 2 diabetes, GLP-1 receptor agonists have shown remarkable efficacy in treating fatty liver. When MASLD progresses to involve liver inflammation and cell damage, it is known as Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly NASH), which can lead to liver cirrhosis and cancer. GLP-1 receptor agonists treat fatty liver through several pathways:

For cardiologists, the most compelling aspect of GLP-1 receptor agonists is their proven ability to protect the heart. In the landmark SELECT trial published in late 2023, semaglutide was shown to reduce the risk of major adverse cardiovascular events (MACE) — including cardiovascular death, non-fatal heart attacks, and non-fatal strokes — by 20% in patients with overweight or obesity and established cardiovascular disease but without diabetes. Similar trials have shown significant reductions in cardiovascular risk for diabetic patients. This cardioprotective effect goes beyond simple weight loss; it is driven by direct improvements in blood pressure, lipid profiles, vascular inflammation, and endothelial function. For a patient with both fatty liver and cardiovascular risk, this represents a dual-benefit therapy that addresses both concerns simultaneously.

At our cardiology clinic located at Paragon Medical Centre on Orchard Road, we take a holistic approach to metabolic and cardiovascular health. We believe that a fatty liver should never be treated in isolation. When a patient presents with MASLD, we perform a comprehensive cardiovascular risk assessment. This includes evaluating vascular health using advanced diagnostic tools like coronary calcium scoring (CAC) and CT coronary angiograms to check for hidden plaque buildup. We also perform a detailed lipid analysis (including Apolipoprotein B and LDL subfractions) and assess insulin resistance. By coordinating care with hepatologists and utilizing modern metabolic therapies like GLP-1 receptor agonists, we help patients reverse liver fat, achieve healthy weights, and significantly lower their risk of heart attacks.